First-in-Class PARP1 Selective Inhibitor Saruparib Shines in

Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.

Related Keywords

Texas , United States , Houston , Timothy Yap , Therapeutics Discovery Division , Translational Research , University Of Texas Md Anderson Cancer Center , Khalifa Institute For Personalized Cancer Therapy , Clinical Development , Investigational Cancer Therapeutics , Phasei Program , Neck Medical Oncology , Cancer Center , Khalifa Institute , Personalized Cancer , Project Optimus ,